- Real-World Experience of the Efficacy and Safety of Upadacitinib 15 mg in Patients with Atopic Dermatitis in Korea
-
Na HM, Choi EJ, Jeon SH, Chang ZF, Choi ME, Moon IJ, Jung JM, Lee WJ, Chang SE, Lee MW, Won CH
- KMID: 2539542
- Korean J Dermatol.
- 2023 Feb;61(2):86-91.
Background: Upadacitinib is an oral Janus kinase1 (JAK1)-selective inhibitor, which showed a quick and significant effect on patients with atopic dermatitis in several phase 3 clinical studies. Although, an increasing... -
- CITED
-
- Close
- SHARE
-
- Close
